FDA Adverse Event Injury Summary report: N

GORE EXCLUDER AAA ENDOPROSTHESIS

MDR report key: 3221086 · Received July 3, 2013

Report

Report Number
2953161-2013-00098
Event Type
Injury
Date Received
July 3, 2013
Date of Event
November 5, 2012
Report Date
June 18, 2013
Manufacturer
W. L. GORE & ASSOCIATES
Product Code
MIH
PMA / PMN Number
P020004
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

THE REVIEW OF THE MFG PAPERWORK VERIFIED THAT THIS LOT MET ALL PRE-RELEASE SPECIFICATIONS.

Description of Event or Problem · 1

IN A REVIEW OF PUBLISHED LITERATURE, THESE FINDINGS WERE NOTED: NAKAI M, SATO M, SATO H, SAKAGUCHI H, ET AL. MIDTERM RESULTS OF ENDOVASCULAR ABDOMINAL AORTIC ANEURYSM REPAIR: COMPARISON OF INSTRUCTION-FOR-USE (IFU) CASES AND NON-IFU CASES. (B)(4) JOURNAL OF RADIOLOGY. OF 124 PTS (104 MEN, 20 WOMEN; MEAN AGE OF PTS WITH EXCLUDER IS (B)(6); AGE RANGE (B)(6)) WITH AAA WHO UNDERWENT EVAR WITH THE ZENITH (68 PTS) OR EXCLUDER DEVICE (56) AND WERE ANALYZED, 86 WERE IFU AND 38 NON-IFU. THIS ARTICLE MENTIONS THAT 3 PTS WHO WERE IMPLANTED WITH GORE EXCLUDER AAA ENDOPROSTHESIS HAD TYPE II ENDOLEAKS AND ANEURYSM ENLARGEMENT THAT REQUIRE INTERVENTION. SPECIFIC INFO ON ONE PT WAS OBTAINED FROM NIHON GORE. ON (B)(6) 2011, THIS PT WAS IMPLANTED WITH A GORE EXCLUDER AAA ENDOPROSTHESIS TO TREAT AN ABDOMINAL AORTIC ANEURYSM. THE FINAL ANGIOGRAM REVEALED NO ENDOLEAK AND THE PHYSICIAN COMPLETED THE PROCEDURE. ON UNK DATE, APPROX ONE YEAR LATER, F/U IMAGE REVEALED A TYPE II ENDOLEAK, LEADING TO ANEURYSM ENLARGEMENT OF MORE THAN 5MM. THE ORIGIN OF THE ENDOLEAK WAS INFERIOR MESENTERIC ARTERY. ON (B)(6) 2012, AN INTERVENTION OCCURRED WHEREBY THE IMA WAS COIL EMBOLIZED. THE ENDOLEAK WAS RESOLVED AND THE PT TOLERATED THE PROCEDURE.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
303515 GORE EXCLUDER AAA ENDOPROSTHESIS MIH / SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT MIH W. L. GORE & ASSOCIATES 9173707

Patients

Seq Age Sex Outcome Treatment
1 70 YR Hospitalization| R (B)(4)| IMPLANTED: